Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.38 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | TDO2 | P48775 | 3/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565971 | 0.85 | ALDH1A1 (0.38) | ALDH1A1IDO1TDO2 | |
| SCHEMBL8807193 | 0.80 | TYR (0.48) | TYRALDH1A1CYP2A6ALDH1A3ADRB2 | |
| SCHEMBL31073154 | 0.80 | TYR (0.48) | TYRALDH1A1CYP2A6ALDH1A3ADRB2 | |
| SCHEMBL6124179 | 0.80 | SLC6A3 (0.45) | ALDH1A1IDO1TDO2KMT2ASMN1; SMN2 | |
| SCHEMBL31073297 | 0.80 | TYR (0.48) | TYRALDH1A1CYP2A6ALDH1A3ADRB2 | |
| SCHEMBL30748256 | 0.79 | LMNA (0.33) | ALDH1A1IDO1TDO2ATML3MBTL1 | |
| SCHEMBL31518250 | 0.78 | ALDH1A1 (0.43) | ALDH1A1IDO1TDO2ATML3MBTL1 | |
| Benzaldehyde SCHEMBL5235499 | 0.77 | ALDH1A1 (0.44) | TYRALDH1A1CYP2A6ALDH1A3ADRB2 | |
| SCHEMBL24512659 | 0.75 | TYR (0.50) | TYRALDH1A1CYP2A6ALDH1A3IDO1 | |
| SCHEMBL29565620 | 0.75 | HTT (0.35) | HTTKDM4ESMN1; SMN2LMNADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1750706-B1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | Univ Virginia Patent Found (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9133136-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-11-06 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8642610-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-02-04 | — | — | US | disclosed |
| US-8298512-B2 | Methods of determining β-III tubulin expression | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-08-09 | — | — | US | disclosed |
| US-8178545-B2 | Dual small molecule inhibitors of cancer and angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2012-05-15 | — | — | US | disclosed |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-18 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329805-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | TYR 1959/4885ALDH1A1 2004/4885CYP2A6 3453/4885 |
| US-20070134161-A1 | METHODS OF DETERMINING BETA-III TUBULIN EXPRESSION | TUBB3, TUBB1, TUBB | TYR 2942/4885ALDH1A1 2066/4885CYP2A6 4392/4885 |
| US-20120202800-A1 | DUAL SMALL MOLECULE INHIBITORS OF CANCER AND ANGIOGENESIS | TP53, MAP2, MAP1LC3B | TYR 1959/4885ALDH1A1 2004/4885CYP2A6 3453/4885 |
| US-20070244098-A1 | Dual Small Molecule Inhibitors of Cancer and Angiogenesis | TP53, MAP2, MAP1LC3B | TYR 1959/4885ALDH1A1 2004/4885CYP2A6 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.